Log in

NASDAQ:UMRXUnum Therapeutics Stock Price, Forecast & News

$2.35
-0.02 (-0.84 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.21
Now: $2.35
$2.35
50-Day Range
$0.43
MA: $2.27
$3.32
52-Week Range
$0.29
Now: $2.35
$3.72
Volume498,134 shs
Average Volume1.37 million shs
Market Capitalization$89.92 million
P/E RatioN/A
Dividend YieldN/A
Beta4.05
Unum Therapeutics Inc., a biopharmaceutical company, develops and commercializes immunotherapy products for cancer. The company is developing ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ non-Hodgkin lymphoma (r/r NHL). Its product portfolio also includes ACTR087 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r NHL; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; ACTR707 used in combination with trastuzumab that is in Phase I clinical trials for treating HER2+ solid tumor cancers; and BOXR1030, which is in pre-clinical stage, targets glypican-3 that improve T cell functionality in the solid tumor microenvironment. Unum Therapeutics Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
Unum Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.31 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:UMRX
CUSIPN/A
Phone617-945-5576

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.50 million
Book Value$1.04 per share

Profitability

Net Income$-31,830,000.00

Miscellaneous

Employees72
Market Cap$89.92 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$2.35
-0.02 (-0.84 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive UMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Unum Therapeutics (NASDAQ:UMRX) Frequently Asked Questions

How has Unum Therapeutics' stock price been impacted by Coronavirus?

Unum Therapeutics' stock was trading at $0.3736 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, UMRX stock has increased by 529.0% and is now trading at $2.35.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Unum Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unum Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Unum Therapeutics
.

When is Unum Therapeutics' next earnings date?

Unum Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Unum Therapeutics
.

How were Unum Therapeutics' earnings last quarter?

Unum Therapeutics Inc (NASDAQ:UMRX) released its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.03. Unum Therapeutics had a negative return on equity of 83.39% and a negative net margin of 99.09%.
View Unum Therapeutics' earnings history
.

What price target have analysts set for UMRX?

3 equities research analysts have issued twelve-month target prices for Unum Therapeutics' stock. Their forecasts range from $3.00 to $4.00. On average, they anticipate Unum Therapeutics' stock price to reach $3.67 in the next year. This suggests a possible upside of 56.0% from the stock's current price.
View analysts' price targets for Unum Therapeutics
.

Has Unum Therapeutics been receiving favorable news coverage?

News coverage about UMRX stock has been trending very positive this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Unum Therapeutics earned a news impact score of 4.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Unum Therapeutics
.

Are investors shorting Unum Therapeutics?

Unum Therapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 362,200 shares, an increase of 14.2% from the April 15th total of 317,300 shares. Based on an average trading volume of 435,800 shares, the short-interest ratio is currently 0.8 days. Approximately 2.5% of the shares of the stock are sold short.
View Unum Therapeutics' Short Interest
.

Who are some of Unum Therapeutics' key competitors?

What other stocks do shareholders of Unum Therapeutics own?

Who are Unum Therapeutics' key executives?

Unum Therapeutics' management team includes the following people:
  • Dr. Charles Wilson, CEO, Pres & Director (Age 55, Pay $807.42k)
  • Mr. Matthew S. Osborne, Chief Financial Officer (Age 48, Pay $517.98k)
  • Dr. Dario Campana, Scientific Founder & Chair of Scientific Advisory Board
  • Mr. John L. Green C.A., C.P.A., Principal Accounting Officer (Age 40)
  • Mr. Larry Weiner, VP of Technical Operations

When did Unum Therapeutics IPO?

(UMRX) raised $75 million in an initial public offering on Thursday, March 29th 2018. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Morgan Stanley and Cowen served as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.

What is Unum Therapeutics' stock symbol?

Unum Therapeutics trades on the NASDAQ under the ticker symbol "UMRX."

Who are Unum Therapeutics' major shareholders?

Unum Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include FIL Ltd (2.18%).
View institutional ownership trends for Unum Therapeutics
.

Which major investors are selling Unum Therapeutics stock?

UMRX stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd.
View insider buying and selling activity for Unum Therapeutics
.

How do I buy shares of Unum Therapeutics?

Shares of UMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Unum Therapeutics' stock price today?

One share of UMRX stock can currently be purchased for approximately $2.35.

How big of a company is Unum Therapeutics?

Unum Therapeutics has a market capitalization of $89.92 million and generates $22.50 million in revenue each year. The company earns $-31,830,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. Unum Therapeutics employs 72 workers across the globe.

What is Unum Therapeutics' official website?

The official website for Unum Therapeutics is www.unumrx.com.

How can I contact Unum Therapeutics?

Unum Therapeutics' mailing address is 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-945-5576 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.